Genmab A/S ADS - ADR

The total asset value of Genmab A/S ADS - ADR stood at $ 45,811 Mln as on 31-Dec-24

The share price of Genmab A/S ADS - ADR is $20.07 (NASDAQ) as of 21-Apr-2025 16:05 EDT. Genmab A/S ADS - ADR has given a return of -19.17% in the last 3 years.

Genmab A/S ADS - ADR has a market capitalisation of $ 12,542 Mln as on 21-Apr-2025. As per Value Research classification, it is a company.

The P/E ratio of Genmab A/S ADS - ADR is 10.89 times as on 21-Apr-2025.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Genmab A/S ADS - ADR and enter the required number of quantities and click on buy to purchase the shares of Genmab A/S ADS - ADR.

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Address: Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500

The CEO & director of Dr. Jan G.J. van de Winkel Ph.D.. is Genmab A/S ADS - ADR, and CFO & Sr. VP is Dr. Jan G.J. van de Winkel Ph.D..

There is no promoter pledging in Genmab A/S ADS - ADR.

Some of the close peers are:

No, TTM profit after tax of Genmab A/S ADS - ADR was $0 Mln.